Last updated: September 1, 2026
Flotufolastat F-18, marketed in the U.S. as Posluma, is an FDA-approved fluorine-18 prostate-specific membrane antigen (PSMA) PET imaging agent developed by Blue Earth Diagnostics, a Bracco company. It is not a gallium product. The approved agent uses fluorine-18, while gallium-68 PSMA products such as Illuccix and Locametz are competing radiopharmaceuticals.[1]
Posluma entered a rapidly expanding prostate-cancer imaging market dominated by Lantheus Holdings’ Pylarify and supported by growing PSMA PET adoption. Its commercial opportunity is substantial, but its financial trajectory is constrained by competition, radiopharmacy capacity, reimbursement execution, and the absence of publicly disclosed product-level revenue from Blue Earth Diagnostics.
What is flotufolastat F-18 and how does it differ from gallium PSMA agents?
Flotufolastat F-18 is a radiolabeled PSMA ligand used with PET imaging to identify PSMA-positive lesions in men with prostate cancer. The FDA approved Posluma on May 25, 2023, for men with:
- Suspected metastasis who are candidates for initial definitive therapy; or
- Suspected recurrence based on elevated prostate-specific antigen after prior treatment.[1]
The active radioactive isotope is fluorine-18, not gallium-68.
| Product |
Isotope |
Company |
U.S. status |
Principal commercial distinction |
| Posluma, flotufolastat F-18 |
F-18 |
Blue Earth Diagnostics/Bracco |
FDA approved in 2023 |
F-18 production and distribution model |
| Pylarify, piflufolastat F-18 |
F-18 |
Lantheus |
FDA approved in 2021 |
Established U.S. PSMA PET market leader |
| Illuccix, gozetotide injection |
Ga-68 |
Telix |
FDA approved in 2021 |
Gallium generator and centralized production options |
| Locametz, gozetotide kit |
Ga-68 |
Novartis |
FDA approved in 2022 |
Kit-based Ga-68 PSMA imaging |
| Axumin, fluciclovine F-18 |
F-18 |
Blue Earth Diagnostics |
FDA approved in 2016 |
Earlier-generation prostate-cancer imaging agent |
F-18 has a physical half-life of approximately 110 minutes, compared with approximately 68 minutes for gallium-68. The longer half-life can support wider geographic distribution from centralized production sites. Gallium-68 products can offer operational flexibility through generators or local radiopharmacy production, although their shorter half-life places greater pressure on scheduling and distribution.[2]
How large is the market for PSMA PET imaging?
The addressable market is expanding because PSMA PET is moving into both initial staging and biochemical recurrence. The main demand drivers are:
- The large population of men diagnosed with prostate cancer.
- Rising use of molecular imaging before definitive treatment.
- Increased detection of biochemical recurrence after surgery or radiation.
- Clinical adoption of PSMA PET in treatment planning.
- Medicare and commercial reimbursement for approved PSMA imaging.
The market is concentrated in the United States, where FDA approvals and reimbursement have allowed rapid deployment. Europe and other regions also have significant potential, but regulatory, reimbursement, isotope-supply, and local manufacturing requirements make international expansion more complex.
The commercial market is not limited to the price of the radiopharmaceutical. Revenue is generated across the imaging chain, including radiotracer sales, radiopharmacy preparation, PET/CT utilization, hospital technical fees, physician interpretation, and oncology referral activity.
What is the competitive position of Posluma?
Posluma entered after Pylarify had established the category commercially. Lantheus reported $1.34 billion in total revenue in 2023, with Pylarify as a major growth product and a central contributor to the company’s oncology imaging business.[3] Lantheus does not disclose all product economics in a format that allows direct comparison with Posluma.
Posluma’s competitive strengths are:
- F-18’s longer half-life relative to Ga-68.
- Blue Earth’s prior experience commercializing Axumin.
- Bracco’s global diagnostic-imaging infrastructure.
- A labeled indication covering both initial staging and suspected recurrence.
- Potential access to existing radiopharmacy and hospital relationships.
Its disadvantages are:
- Later entry than Pylarify.
- A market with established physician and radiology workflows.
- Competition from both F-18 and Ga-68 products.
- Limited publicly disclosed commercial execution data.
- Dependence on local PET capacity and isotope supply.
How does Posluma compare with Pylarify?
Both products use F-18 and target PSMA. Their commercial competition is therefore less dependent on isotope logistics than the competition between F-18 products and Ga-68 products.
| Factor |
Posluma |
Pylarify |
| FDA approval |
2023 |
2021 |
| Isotope |
F-18 |
F-18 |
| Developer |
Blue Earth Diagnostics |
Lantheus |
| Commercial maturity |
Later-stage launch |
Established category leader |
| Corporate platform |
Bracco |
Lantheus imaging portfolio |
| Key risk |
Share capture against incumbent |
Competitive erosion and pricing pressure |
Pylarify’s first-mover position gives Lantheus advantages in payer contracting, radiologist familiarity, production-site density, and referral relationships. Posluma can gain share where Blue Earth has strong radiopharmacy access, where hospitals prefer supplier diversification, or where local delivery economics are favorable.
What is the financial trajectory for flotufolastat F-18?
No reliable public filing provides standalone Posluma revenue, gross margin, operating income, or cash-flow data. Blue Earth Diagnostics is owned by Bracco, a privately held Italian healthcare company, and does not report Posluma as a separately listed public-company segment.
The financial trajectory therefore must be assessed through commercial indicators rather than a reported product P&L.
| Financial driver |
Directional effect on Posluma |
| PSMA PET adoption |
Positive |
| U.S. reimbursement |
Positive if coverage and payment remain stable |
| Pylarify market share |
Negative |
| Ga-68 competition |
Negative to neutral |
| F-18 distribution range |
Positive |
| Radiopharmacy manufacturing cost |
Negative if production density is low |
| PET/CT capacity |
Limits near-term volume |
| Bracco distribution infrastructure |
Potentially positive |
| Product-specific disclosure |
Limits external valuation precision |
The likely early financial profile is characterized by high commercial-investment requirements, manufacturing-site expansion, sales-force deployment, payer contracting, and physician education before full volume leverage is reached. Radiopharmaceutical economics can improve materially when production facilities operate at higher utilization, because fixed infrastructure and quality-control costs are spread over more doses.
Posluma’s revenue ceiling depends less on prostate-cancer prevalence than on the percentage of eligible patients receiving PSMA PET, the number of scans performed per patient, reimbursement per dose, and the supplier’s ability to deliver product within the isotope’s usable window.
What reimbursement factors affect Posluma revenue?
Medicare reimbursement is central to the U.S. business model. Payment generally involves several components:
- The radiopharmaceutical or tracer charge.
- The PET technical component.
- The physician interpretation component.
- Hospital outpatient or physician-office payment rules.
- Payer-specific coverage policies.
The Centers for Medicare & Medicaid Services has established payment pathways for diagnostic radiopharmaceuticals and PET imaging, but reimbursement can vary by setting and coding structure.[4] Commercial insurers may apply medical-necessity criteria based on indication, prior treatment, PSA trends, and clinical guidelines.
Reimbursement risk is greater in biochemical recurrence and lower-volume community settings, where authorization delays or limited PET infrastructure can reduce scan utilization. Posluma’s commercial performance will benefit if PSMA PET becomes routine in treatment planning rather than remaining concentrated at academic cancer centers.
What manufacturing and supply barriers affect flotufolastat F-18?
Posluma requires an F-18 production and radiopharmacy network. The core manufacturing barriers are:
- Access to cyclotron capacity.
- Radiochemistry production under current good manufacturing practices.
- Dose calibration and quality-control release.
- Distribution scheduling within the F-18 half-life.
- Backup production capability.
- Geographic coverage of PET centers.
F-18 does not eliminate supply-chain risk. Its longer half-life improves distribution relative to Ga-68, but the product still requires tightly coordinated manufacturing, release, shipment, and administration. A production outage can affect multiple downstream imaging sites.
Bracco’s existing diagnostic-imaging infrastructure may reduce the time and cost required to scale commercial operations. It does not remove the need for regional manufacturing density or reliable last-mile delivery.
What patents protect Posluma and when could generic competition emerge?
Posluma is a radiopharmaceutical rather than a conventional small-molecule therapy. Its defensibility can involve:
- The PSMA-binding ligand.
- Radiolabeling chemistry.
- Precursor compounds.
- Formulation and stability.
- Manufacturing methods.
- PET imaging methods.
- Regulatory exclusivity.
- Trade secrets covering production and quality systems.
Publicly available sources do not provide a sufficiently reliable, consolidated list of all patents, expiration dates, Orange Book listings, and settlement terms applicable specifically to Posluma. Product-level patent analysis is therefore less transparent than for many oral drugs.
Traditional generic substitution is also less straightforward. A competing manufacturer would need to establish an equivalent radiopharmaceutical, obtain regulatory approval, build compliant production capacity, and supply doses within the required distribution window. Manufacturing know-how and radiopharmacy infrastructure can create practical barriers even where patent protection is limited.
Because Posluma is a diagnostic radiopharmaceutical, biosimilar risk is not the relevant framework. The principal risks are competing branded PSMA tracers, authorized or abbreviated regulatory entrants, compounded or locally prepared products where legally permitted, and substitution driven by hospital procurement.
Are there Paragraph IV challenges or patent litigation involving Posluma?
No widely reported Paragraph IV challenge or major public patent litigation against Posluma had established a material near-term launch threat through the available public record. Paragraph IV litigation is more common for high-volume conventional drugs with extensive Orange Book patent listings. Radiopharmaceutical competition is more likely to develop through rival products and manufacturing scale than through conventional generic litigation.
The absence of a disclosed challenge does not create a guaranteed exclusivity period. Commercial protection will depend on the actual patent portfolio, regulatory exclusivity, manufacturing complexity, and competing PSMA product approvals.
What licensing deals support the Posluma business?
Blue Earth Diagnostics is part of Bracco, which acquired the company in 2017.[5] The acquisition provided Bracco with a commercial platform in molecular imaging and prostate-cancer diagnostics.
Publicly disclosed materials do not establish a major separate licensing transaction that determines Posluma’s economics in the same way that a royalty-bearing partnered drug might. The primary strategic asset is the combination of Blue Earth’s radiopharmaceutical development and commercialization capabilities with Bracco’s global imaging infrastructure.
What generic launch scenarios exist for Posluma?
The most plausible market-entry scenarios are:
Base case
PSMA PET utilization expands, but Pylarify retains a leading position. Posluma achieves a durable secondary share through regional supply, hospital contracting, and Bracco’s commercial network.
Upside case
PSMA PET becomes standard across initial staging and recurrence. Blue Earth expands production coverage, wins hospital contracts, and establishes Posluma as a major alternative to Pylarify and Ga-68 products.
Downside case
Pylarify maintains strong physician preference, Ga-68 products secure durable institutional relationships, and reimbursement or production constraints limit Posluma’s utilization.
A conventional low-price generic launch is less likely to be the first source of erosion than branded radiopharmaceutical competition. The competitive market may therefore remain differentiated by supply reliability, scan scheduling, image quality, payer access, and local economics.
What is the investment outlook for Posluma?
Posluma has meaningful market exposure to a growing diagnostic category but limited external financial transparency. Investors assessing the asset should focus on:
- Dose volume and production-site expansion.
- Hospital and radiology-center adoption.
- Reimbursement by care setting.
- Share relative to Pylarify.
- Competition from Illuccix and Locametz.
- Product availability and delivery performance.
- Expansion into additional geographic markets.
- Evidence of recurring use in biochemical recurrence.
- Bracco’s segment reporting and any future product-level disclosure.
The asset’s value is strategic as well as financial. It strengthens Bracco’s position in molecular imaging, but its standalone contribution cannot be calculated from public filings with precision.
Key Takeaways
- Flotufolastat F-18 is Posluma, an F-18 PSMA PET agent approved by the FDA in May 2023.
- It is not a gallium-68 product. Gallium PSMA competitors include Illuccix and Locametz.
- Pylarify has the strongest disclosed U.S. commercial position because it entered the market earlier and is backed by Lantheus.
- Posluma’s principal advantages are F-18 distribution characteristics, Bracco’s infrastructure, and its broad prostate-cancer imaging label.
- Blue Earth and Bracco do not publicly disclose standalone Posluma revenue or profitability.
- The principal commercial barriers are reimbursement, PET capacity, radiopharmacy scale, isotope supply, and physician adoption.
- Biosimilar risk is irrelevant. The main threats are branded PSMA competitors and potential radiopharmaceutical entrants.
- No major public Paragraph IV challenge or patent litigation event had established a near-term generic threat in the available public record.
- Posluma’s financial trajectory is likely to depend on market-share capture from established PSMA PET products rather than on expansion of the overall prostate-cancer diagnosis market alone.
FAQs About Flotufolastat F-18
Is flotufolastat F-18 the same as Pylarify?
No. Both are F-18 PSMA PET agents, but Posluma contains flotufolastat F-18 and Pylarify contains piflufolastat F-18. They are separate products from different companies.
Does Posluma contain gallium-68?
No. Posluma uses fluorine-18. Gallium-68 is used in competing products including Illuccix and Locametz.
Who owns Posluma?
Blue Earth Diagnostics developed Posluma and is owned by Bracco, a privately held Italian healthcare company.
Can Posluma be used for routine prostate-cancer screening?
No. The FDA indication covers specific staging and suspected-recurrence settings. It is not approved as a general-population screening test.
What is the main commercial risk for Posluma?
The largest commercial risk is slower-than-expected share capture against Pylarify and other established PSMA PET products, compounded by reimbursement constraints and the operational demands of F-18 radiopharmaceutical distribution.
References
- U.S. Food and Drug Administration. (2023). Posluma (flotufolastat F 18) prescribing information.
- U.S. Food and Drug Administration. (2021-2023). Prescribing information for Pylarify, Illuccix, and Locametz.
- Lantheus Holdings, Inc. (2024). 2023 annual report on Form 10-K.
- Centers for Medicare & Medicaid Services. (2023-2024). Medicare coverage and payment policies for PET radiopharmaceuticals and diagnostic imaging.
- Bracco S.p.A. (2017). Bracco acquisition of Blue Earth Diagnostics.
